See more : Sogeclair SA (SOG.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Sansure Biotech Inc. (688289.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sansure Biotech Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Wellnet Corporation (2428.T) Income Statement Analysis – Financial Results
- Art Group Holdings Limited (0565.HK) Income Statement Analysis – Financial Results
- Rapicut Carbides Limited (RAPICUT.BO) Income Statement Analysis – Financial Results
- Tower Semiconductor Ltd. (TSEM) Income Statement Analysis – Financial Results
- Avatar Ventures Corp. (ATAR) Income Statement Analysis – Financial Results
Sansure Biotech Inc. (688289.SS)
About Sansure Biotech Inc.
Sansure Biotech Inc. develops and sells upstream nucleic acid extraction kits, real time PCR diagnostic and research kits, and fluorescence systems in China and internationally. The company offers novel coronavirus nucleic acid diagnostic kits; viral hepatitis and AIDS, blood screening, and extraction kits; cancer-related biomarkers; and kits for respiratory tract diseases, STDs, digestive tract diseases, prenatal and postnatal care, and genetic diseases, as well as instruments and other consumables. It serves hospitals and laboratories. The company was founded in 2008 and is based in Changsha, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.01B | 6.45B | 4.51B | 4.76B | 365.39M | 303.45M | 224.60M |
| Cost of Revenue | 286.64M | 2.66B | 1.28B | 969.95M | 127.31M | 126.05M | 112.72M |
| Gross Profit | 720.48M | 3.79B | 3.24B | 3.79B | 238.08M | 177.40M | 111.88M |
| Gross Profit Ratio | 71.54% | 58.83% | 71.67% | 79.64% | 65.16% | 58.46% | 49.81% |
| Research & Development | 196.28M | 331.83M | 187.50M | 82.77M | 38.95M | 35.68M | 27.64M |
| General & Administrative | 13.93M | 102.63M | 42.57M | 38.73M | 11.88M | 9.86M | 11.32M |
| Selling & Marketing | 192.38M | 732.23M | 392.33M | 519.80M | 123.09M | 99.31M | 69.96M |
| SG&A | 206.31M | 834.86M | 434.90M | 558.53M | 134.98M | 109.17M | 81.28M |
| Other Expenses | -109.57M | 95.46M | 44.50M | 39.57M | 14.73M | -1.01M | 30.36M |
| Operating Expenses | 298.69M | 1.26B | 666.90M | 680.88M | 188.66M | 163.74M | 127.11M |
| Cost & Expenses | 579.66M | 3.92B | 1.95B | 1.65B | 315.97M | 289.79M | 239.83M |
| Interest Income | 54.67M | 48.35M | 32.53M | 16.73M | 205.99K | 5.07M | 6.10M |
| Interest Expense | 5.53M | 2.09M | 829.41K | 508.17K | 519.64K | 3.17M | 16.35M |
| Depreciation & Amortization | 136.77M | 97.43M | 58.95M | 28.67M | 22.54M | 21.68M | 20.63M |
| EBITDA | 574.93M | 2.44B | 2.67B | 3.10B | 68.62M | 32.46M | 39.68M |
| EBITDA Ratio | 57.09% | 40.78% | 57.62% | 65.33% | 18.87% | 12.66% | 17.98% |
| Operating Income | 427.46M | 2.34B | 2.62B | 3.09B | 47.52M | 11.70M | -27.73M |
| Operating Income Ratio | 42.44% | 36.27% | 58.07% | 64.79% | 13.00% | 3.86% | -12.35% |
| Total Other Income/Expenses | -16.98M | -23.89M | -5.58M | -15.87M | -2.06M | -1.01M | 30.36M |
| Income Before Tax | 410.48M | 2.32B | 2.62B | 3.07B | 45.46M | 10.69M | 2.63M |
| Income Before Tax Ratio | 40.76% | 35.90% | 57.95% | 64.46% | 12.44% | 3.52% | 1.17% |
| Income Tax Expense | 62.31M | 379.21M | 373.68M | 453.56M | 5.98M | 3.93M | 13.28M |
| Net Income | 363.72M | 1.94B | 2.24B | 2.62B | 39.48M | 6.76M | -10.65M |
| Net Income Ratio | 36.12% | 30.03% | 49.68% | 54.94% | 10.80% | 2.23% | -4.74% |
| EPS | 0.64 | 3.35 | 3.79 | 4.42 | 0.07 | 0.02 | -0.03 |
| EPS Diluted | 0.64 | 3.35 | 3.79 | 4.42 | 0.07 | 0.02 | -0.03 |
| Weighted Avg Shares Out | 572.18M | 578.69M | 591.66M | 592.00M | 592.00M | 358.90M | 358.90M |
| Weighted Avg Shares Out (Dil) | 572.18M | 578.69M | 591.66M | 592.00M | 592.00M | 358.90M | 358.90M |
Source: https://incomestatements.info
Category: Stock Reports